Nice! thanks to the Yahoo MB for the head's up on Zack's initiation of coverage and $2.50 target !
Anyone on this list use NP-1? or know of a compounding pharmacist familiar with NP-1 Rx ?
EpiCept Corp: Initiating Coverage With Outperform Rating
We are initiating coverage of EpiCept (EPCT) with an Outperform rating. Our price target is $2.50 per share. Our call is based on the strong fundamentals of the Company. EpiCept’s shares are undervalued in our view. We see a favorable reward/risk profile for the Company at this point. Therefore, we have an Outperform rating for the Company. Risks associated with our call are weak balance sheet and regulatory uncertainties for its major drug candidates.